OX-40 receptor belongs to tumor necrosis factor (TNF) superfamily and OX-40 interactions plays an important role in the development of various autoimmune and inflammatory diseases. OX-40 interactions are one of the most important costimulatory pathways that have determined the scope of CD4 and CD8 T cell immunity in various inflammatory conditions. OX-40 and some of its related family members, is an important signaling pathway in T cells which cannot be ignored in explaining their important role in T cell immunity. Beyond the CTLA-4 and PD-1 pathways, the targeting of OX-40 receptor has demonstrated most positive clinical results. Hence, it is among the most promising emerging checkpoints in development for the better drug development and other interventions for the treatment of various diseases.
OX-40 RECEPTOR AGONIST THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)
OX-40 is a costimulatory receptor that binds to its only known ligand, OX-40L, initiating cellular signaling events required for full activation of T cells following their recognition of a foreign antigen. OX-40 agonists mimic the effect of OX-40L, and boost the OX-40 signaling, and thereby results in overcoming the suppression of the anti-tumor immune response in cancer patients. OX-40 agonists in combination with checkpoint immunotherapies, surgical resection, and radiotherapy has demonstrated promising results for the treatment of cancer patients.
Drug manufacturing companies are constantly involved in the quest to find better and new treatment strategies by targeting OX-40 receptor which can be effective as anti-cancer therapies. Various companies are developing drug candidates using different technologies for the development of effective and better drugs, which is driving the growth of the pipeline.
As of October 2017, the OX-40 receptor agonist therapeutics pipeline comprises of approximately nine drug candidates in different stages of development.
Some of the key players developing drugs as OX-40 receptor agonist for the treatment of various indications include MedImmune, LLC, Agenus Inc., Pfizer Inc., GlaxoSmithKline plc and others.